Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
Alzheimer's disease (AD) is characterized by a progressive cognitive decline involving a multifactorial pathophysiology, including epigenetic dysregulation.
Why it matters
This preclinical study reports a new brain-penetrant G9a inhibitor, FLAV-27, that reduced amyloid and tau pathology in animal models of Alzheimer's disease. It is early animal research and has not been shown to treat, cure, or prevent Alzheimer's disease in people.
-
The table shows a comparative analysis stratified by young-onset AD (YOAD, onset <65 years) and late-onset AD (LOAD, onset ≥65 years).
Why it matters
In this autopsy series, socioeconomic deprivation and most medical comorbidities were not linked to the age when Alzheimer's symptoms began. People with young-onset Alzheimer's had faster cognitive decline and longer disease duration despite higher education and less cerebrovascular disease than those with late-onset disease.
-
Overall SNP‐based heritability estimates using this restricted set of variants varied: AA ( h 2 = 0.13, SE=0.05), NHW ( h 2 = 0.14, SE=0.01), AsA ( h 2 = 0.29, SE=0.09) and HL ( h 2 = 0.48, SE=0.17).
Why it matters
SNP-based heritability estimates for Alzheimer's disease varied across ancestry groups, ranging from 0.13 in African Americans to 0.48 in Hispanics/Latinos. These findings highlight that ancestry-specific genetic contributors for Alzheimer's disease remain to be identified.
-
Finally, at the RHOJ locus, the rare allele was associated with increased tTau ( p ‐value=4.74×10 ‐05 ) and pTau181 ( p ‐value=4.07×10 ‐07 ), and decreased Aβ42/40 ratio ( p ‐value=4.32×10 ‐05 ).
Why it matters
Four genome-wide significant loci associated with Alzheimer's disease risk were identified in autosomal dominant mutation carriers. At the RHOJ locus, the rare allele was associated with increased tau and decreased Aβ42/40 ratio.
-
Until recently, accurate early detection of clinical symptoms associated with Alzheimer's disease (AD) and related dementias (ADRD) has been difficult.
Why it matters
This review describes how digital technologies such as speech recordings, ocular scans, and multi-modality sensors with artificial intelligence could enable earlier detection of Alzheimer's disease and related dementias. It discusses a future state of detection and intervention but does not itself test any treatment, cure or prevention.
-
40/100
As the U.S. population ages, Alzheimer's disease and related dementias (ADRD) cases are increasing, resulting in long wait times for specialist care.
Why it matters
This review describes artificial intelligence applications in Alzheimer's disease and related dementias care, including neuroimaging interpretation, digital cognitive assessments, and emerging digital biomarkers. It notes that most of these systems are not yet accessible in clinical practice and does not itself treat, cure or prevent Alzheimer's disease.
-
The Neural Network classifier achieved an accuracy of 91% with a 95% CI ranging from 0.79-0.97 and an AUC of 94%, on the test set after identifying the most significant features for AD prediction.
Why it matters
This study describes an artificial intelligence application whose neural network classifier predicted Alzheimer's disease with 91% accuracy, with two timing variables emerging as key predictors. The authors state that clinical validation is necessary to confirm the practical applicability of these variables.
-
Epidemiological data show that both PD incidence rate and prevalence rate show a significant age-dependent growth trend [3].
Why it matters
This paper discusses combining multimodal medical imaging and artificial intelligence for early diagnosis of Parkinson's disease, reporting high diagnostic accuracy in cited work. It concerns Parkinson's disease diagnosis and does not test any treatment, cure or prevention of Alzheimer's disease.
-
The relationship between dietary biotin intake and cognitive function remains unclear.
Why it matters
This study found that higher dietary biotin intake was associated with reduced risk of all-cause dementia and Alzheimer's disease, with systemic inflammation possibly mediating the association. It suggests that biotin intake may be linked to dementia risk, but it does not show that taking biotin prevents dementia.
-
Significant regional differences in AD dementia prevalence were observed (F = 126.56, p < 0.05).
Why it matters
Using machine learning on county-level data, this cross-sectional study found that built environment and social vulnerability variables predicted Alzheimer's disease dementia prevalence, with grocery store density and walkability emerging as key variables in the Northeast. Because it is cross-sectional, it shows associations and cannot establish that these environmental factors cause or prevent dementia.
-
One hundred and eighteen years have passed since Alzheimer's disease (AD) was first diagnosed by Alois Alzheimer as a multifactorial and complex neurodegenerative disorder with psychiatric components.
Why it matters
This review discusses how neuroinflammation, genetics such as APOE4, blood-brain barrier breakdown, and conditions like type 2 diabetes may contribute to Alzheimer's disease. It is a broad overview, not a new treatment or cure, and it does not report a tested therapy.
-
> 0.95) and is present in all African ancestry tested.
Why it matters
This study investigated an African-specific haplotype harboring a protective locus for APOE ε4 carriers that significantly reduces Alzheimer disease risk. It found the protective haplotype is unique within segmental duplications, is present in all African ancestry tested but not other ancestries, and is associated with differences in DNA methylation and an expanded VNTR.
-
In total, 24 recommendations were developed covering the research landscape and priorities within research in AD following a possible approval, potential impact on health care systems and diagnostic pathways, and communication to patients about anti-amyloid antibodies.
Why it matters
Individual members of the European Alzheimer's Disease Consortium issued 24 recommendations on how anti-amyloid antibody therapy could be introduced in Europe if approved, including effects on health care systems and diagnostic pathways. They call the antibodies a substantial innovation but also say new compounds with other mechanisms are needed and recommendations must be updated as evidence emerges.
-
On average, people with dementia fall more often than their age-matched peers, with serious consequences, yet the underlying reasons remain poorly understood.
Why it matters
This narrative review suggests that diminished inhibitory control may contribute to poor balance and falls in people with Alzheimer's disease, and that assessing inhibitory control could improve falls risk predictions and aid AD detection. These are hypotheses from a review, not confirmed clinical tools or treatments.
-
Alzheimer disease (AD) is the most common form of dementia with hallmarks of β-amyloid deposits, neurofilament tangles, synaptic loss and neuronal death in the patient's brain.
Why it matters
This review describes autophagy as a protective process in the brain and notes that autophagy-related genes are decreased in post-mortem Alzheimer's brains, with roles in neurons, glia, and blood vessels. It provides insights for future research but does not report an effective treatment.
-
Alzheimer's dementia (AD) is a degenerative brain disease characterized by a decline in cognitive function and memory.
Why it matters
Using the Oasis Longitudinal dataset, an ensemble machine learning method with soft voting and Gradient Boosting achieved 97% accuracy in predicting Alzheimer's dementia. This is a prediction model only and does not show how to treat, cure, or prevent the disease.
-
score 0.8323, although only the AUC was statistically significantly different) and other AI-based models.
Why it matters
Artificial intelligence-based text classification methods outperformed a standard algorithm for identifying patients with Alzheimer's disease and related dementias from electronic health records. This is about improving automated identification and does not address treating, curing, or preventing the disease.
-
Amyloid proteins have long been in the spotlight for being involved in many degenerative diseases including Alzheimer´s, Parkinson´s or type 2 diabetes, which currently cannot be prevented and for which there is no effective treatment or cure.
Why it matters
This review covers inhibitors acting directly on the amyloidogenic pathway at the monomer, oligomer or fibril level, and discusses preclinical and clinical advances including nanomaterial-based inhibitors. It notes that amyloid-related diseases including Alzheimer's currently cannot be prevented and have no effective treatment or cure.
-
Alzheimer’s disease (AD) is a neurodegenerative disorder that affects millions of people worldwide.
Why it matters
This review examines how MRI, SPECT and PET imaging can detect Alzheimer's-related biomarkers such as amyloid beta plaques and tau tangles, and help with early detection, distinguishing the disease from other conditions, and evaluating treatment effectiveness. It is a review of imaging's role and does not itself test a treatment, cure or prevention.
-
IntroductionThe prevalence of neurodegenerative diseases has significantly increased, necessitating a deeper understanding of their symptoms, diagnostic processes, and prevention strategies.
Why it matters
This narrative review of 31 studies examines AI methods using imaging to tell Alzheimer's disease apart from frontotemporal dementia. It is about improving diagnosis, not about treating, curing, or preventing Alzheimer's disease.
-
40/100
Alzheimer's disease (AD) and frontotemporal dementia (FTD) are the most burdensome neurodegenerative disorders in older populations as they pose significant challenges because of subtle cognitive decline in the initial stages.
Why it matters
This study used EEG time-domain analysis with Hjorth parameters to distinguish Alzheimer's disease, frontotemporal dementia and cognitively normal subjects with high classification accuracy. It concerns diagnosis and assessment of cognitive decline, not treatment, cure or prevention.
-
A century ago, German neurologist Alois Alzheimer documented the first case of Alzheimer's disease (AD), illuminating cognitive impairments associated with the presence of abnormal protein clusters, including amyloid plaques and tau tangles, within the brain.
Why it matters
This paper notes that decades without successful drug development targeting amyloid-β have generated skepticism about whether clearing amyloid is an effective treatment strategy. It discusses chemical-driven amyloid clearance as a possible approach for therapy and diagnosis.
-
The association between poor cardiovascular health and cognitive decline as well as dementia progression has been inconsistent across studies.
Why it matters
This Mendelian randomization study found no direct causal relationship between coronary artery disease and Alzheimer's disease. It is about whether one condition causes the other, not about treating, curing or preventing Alzheimer's disease.
-
Hyperphosphorylation of the microtubule-associated protein tau is hypothesized to lead to the development of neurofibrillary tangles in select brain regions during normal aging and in Alzheimer disease (AD).
Why it matters
This study used biochemical methods to measure tau and other neuronal proteins in the submandibular gland and frontal cortex across different stages of Alzheimer's disease. It is a descriptive analysis of tissue and does not test any treatment, cure, or prevention.
-
Alzheimer's disease (AD), also called senile dementia, is the most common neurological disorder.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment
- Interaction Between Diet and Microbiota in the Pathophysiology of Alzheimer's Disease: Focus on Polyphenols and Dietary Fibers
- Hypothesis: Alzheimer's disease is a phylogenetic disease
- The dysregulation of intracellular calcium in Alzheimer disease
- BrainAGE in Mild Cognitive Impaired Patients: Predicting the Conversion to Alzheimer's Disease
- Exploring the Therapeutic Potential of Chalcones in Alzheimer’s Disease: Mechanistic Insights and SAR Perspectives
- Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies
- Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer Disease
- Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society
- The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and its contributions to understanding Alzheimer's disease in Down syndrome: A decade of discovery